SG11201810146SA - Adenosine derivatives for use in the treatment of cancer - Google Patents
Adenosine derivatives for use in the treatment of cancerInfo
- Publication number
- SG11201810146SA SG11201810146SA SG11201810146SA SG11201810146SA SG11201810146SA SG 11201810146S A SG11201810146S A SG 11201810146SA SG 11201810146S A SG11201810146S A SG 11201810146SA SG 11201810146S A SG11201810146S A SG 11201810146SA SG 11201810146S A SG11201810146S A SG 11201810146SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- cardiff
- pct
- cancer
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1111111111 0111011110111110101111111 01111111111111111111111111 MEV 1111 III1 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2017/207989 Al 07 December 2017 (07.12.2017) WIP0 I PCT (51) International Patent Classification: (74) Agent: HGF LIMITED; 1 City Walk, Leeds West York- C07H 19/167 (2006.01) A61P 35/00 (2006.01) shire LS11 9DX (GB). CO7H 19/20 (2006.01) A61P 35/02 (2006.01) A61K 31/7076 (2006.01) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (21) International Application Number: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, PCT/GB2017/051554 CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (22) International Filing Date: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, 31 May 2017 (31.05.2017) HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (25) Filing Language: English MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (26) Publication Language: English PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (30) Priority Data: TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. 1609602.6 01 June 2016 (01.06.2016) GB (84) Designated States (unless otherwise indicated, for every (71) Applicant: NUCANA BIOMED LIMITED [GB/GB]; 10 kind of regional protection available): ARIPO (BW, GH, Lochside Place, Edinburgh Scotland EH12 9RG (GB). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (72) Inventors: GRIFFITH, Hugh; c/o NuCana BioMed Lim-TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, ited, PO Box 10, Lochside Place, Edinburgh Scotland EH12 EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, —SchoolPharmacy 9RG (GB). SERPI, Michaela; c/o of MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, & Pharmaceutical Sciences, Cardiff University, Redwood TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, = Building, King Edward VII Avenue, Cardiff South Glam- KM, ML, MR, NE, SN, TD, TG). organ CF10 3NB (GB). SLUSARCZYK, Magdalena; c/ = o School of Pharmacy & Pharmaceutical Sciences, Cardiff _ Published: University, Redwood Building, King Edward VII Avenue, _ = with international search report (Art. 21(3)) Cardiff South Glamorgan CF10 3NB (GB). = (72) Inventor: MCGUIGAN, Christopher (deceased). = (54) Title: ADENOSINE DERIVATIVES FOR = = = = = = = 0 = USE IN THE TREATMENT OF CANCER H 2 N ,-, t:I ' P R4 I 0 GC t:I ' IN © N IN © N efts (57) : The present invention and their use in the treatment of cancer. P'' relates to chemical compounds R OH OH ( 1 ) of formula (I) as defined in the amended claims, their preparation
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1609602.6A GB201609602D0 (en) | 2016-06-01 | 2016-06-01 | Chemical compounds |
| PCT/GB2017/051554 WO2017207989A1 (en) | 2016-06-01 | 2017-05-31 | Adenosine derivatives for use in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201810146SA true SG11201810146SA (en) | 2018-12-28 |
Family
ID=56410851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201810146SA SG11201810146SA (en) | 2016-06-01 | 2017-05-31 | Adenosine derivatives for use in the treatment of cancer |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20190375778A1 (en) |
| EP (1) | EP3464308B1 (en) |
| JP (1) | JP2019520345A (en) |
| KR (1) | KR20190015355A (en) |
| CN (1) | CN109563122A (en) |
| AU (1) | AU2017273120A1 (en) |
| BR (1) | BR112018074972A2 (en) |
| CA (1) | CA3025435A1 (en) |
| CL (1) | CL2018003444A1 (en) |
| EA (1) | EA201892802A1 (en) |
| GB (1) | GB201609602D0 (en) |
| IL (1) | IL263120A (en) |
| MX (1) | MX2018014849A (en) |
| PH (1) | PH12018502497A1 (en) |
| SG (1) | SG11201810146SA (en) |
| WO (1) | WO2017207989A1 (en) |
| ZA (1) | ZA201807810B (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
| AU2015352203B2 (en) | 2014-11-28 | 2019-08-15 | NuCana plc | New 2' and/or 5' amino-acid ester phosphoramidate 3'-deoxy adenosine derivatives as anti-cancer compounds |
| RS60600B1 (en) | 2016-05-31 | 2020-08-31 | Kalvista Pharmaceuticals Ltd | Pyrazole derivatives as plasma kallikrein inhibitors |
| GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| GB201609603D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide |
| GB201709471D0 (en) * | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
| GB201715011D0 (en) | 2017-09-18 | 2017-11-01 | Nucana Biomed Ltd | Floxuridine synthesis |
| GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
| RU2020121151A (en) | 2017-11-29 | 2021-12-29 | Калвиста Фармасьютикалз Лимитед | DOSAGE FORMS CONTAINING PLASMA KALLIKREIN INHIBITOR |
| GB201720279D0 (en) | 2017-12-05 | 2018-01-17 | Nucana Biomed Ltd | Anticancer compounds |
| GB201820685D0 (en) | 2018-12-19 | 2019-01-30 | NuCana plc | Synthesis of 8-chloroadenosine derivatives |
| WO2021028645A1 (en) | 2019-08-09 | 2021-02-18 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
| CN113549076B (en) * | 2021-07-23 | 2022-12-06 | 中国药科大学 | Polysubstituted purine compound and preparation method and application thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0505781D0 (en) * | 2005-03-21 | 2005-04-27 | Univ Cardiff | Chemical compounds |
| MX2015006195A (en) * | 2012-11-16 | 2015-12-08 | Univ Cardiff | Process for preparing nucleoside prodrugs. |
| CN103435672A (en) * | 2013-04-25 | 2013-12-11 | 刘沛 | Structure and synthesis of novel nucleoside phosphate prodrug containing substituted benzyl |
| US10030044B2 (en) * | 2013-11-27 | 2018-07-24 | Idenix Pharmaceuticals Llc | Nucleotides for the treatment of liver cancer |
-
2016
- 2016-06-01 GB GBGB1609602.6A patent/GB201609602D0/en not_active Ceased
-
2017
- 2017-05-31 MX MX2018014849A patent/MX2018014849A/en unknown
- 2017-05-31 US US16/305,159 patent/US20190375778A1/en not_active Abandoned
- 2017-05-31 CN CN201780048210.XA patent/CN109563122A/en active Pending
- 2017-05-31 EA EA201892802A patent/EA201892802A1/en unknown
- 2017-05-31 KR KR1020187037541A patent/KR20190015355A/en unknown
- 2017-05-31 EP EP17728920.4A patent/EP3464308B1/en active Active
- 2017-05-31 BR BR112018074972-9A patent/BR112018074972A2/en not_active Application Discontinuation
- 2017-05-31 JP JP2018563087A patent/JP2019520345A/en active Pending
- 2017-05-31 CA CA3025435A patent/CA3025435A1/en not_active Abandoned
- 2017-05-31 AU AU2017273120A patent/AU2017273120A1/en not_active Abandoned
- 2017-05-31 SG SG11201810146SA patent/SG11201810146SA/en unknown
- 2017-05-31 WO PCT/GB2017/051554 patent/WO2017207989A1/en unknown
-
2018
- 2018-11-19 IL IL263120A patent/IL263120A/en unknown
- 2018-11-20 ZA ZA2018/07810A patent/ZA201807810B/en unknown
- 2018-11-26 PH PH12018502497A patent/PH12018502497A1/en unknown
- 2018-11-30 CL CL2018003444A patent/CL2018003444A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017207989A1 (en) | 2017-12-07 |
| EP3464308B1 (en) | 2020-08-19 |
| CN109563122A (en) | 2019-04-02 |
| BR112018074972A2 (en) | 2019-03-12 |
| GB201609602D0 (en) | 2016-07-13 |
| KR20190015355A (en) | 2019-02-13 |
| ZA201807810B (en) | 2021-04-28 |
| EP3464308A1 (en) | 2019-04-10 |
| AU2017273120A1 (en) | 2018-12-06 |
| US20190375778A1 (en) | 2019-12-12 |
| CL2018003444A1 (en) | 2019-05-10 |
| EA201892802A1 (en) | 2019-06-28 |
| CA3025435A1 (en) | 2017-12-07 |
| PH12018502497A1 (en) | 2019-04-08 |
| MX2018014849A (en) | 2019-03-14 |
| JP2019520345A (en) | 2019-07-18 |
| IL263120A (en) | 2018-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201810146SA (en) | Adenosine derivatives for use in the treatment of cancer | |
| SG11201810018TA (en) | Phosphoramidate nucleoside derivatives as anticancer agents | |
| SG11201809064QA (en) | Chimeric neurotoxins | |
| SG11201906223TA (en) | Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer | |
| SG11201804934PA (en) | Novel Compounds | |
| SG11201810034XA (en) | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201908598PA (en) | Compounds useful in the treatment or prevention of a prmt5-mediated disorder | |
| SG11201810423XA (en) | Pd-1 / pd-l1 inhibitors for cancer treatment | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201809922YA (en) | Pyrazole derivatives as plasma kallikrein inhibitors | |
| SG11201807593TA (en) | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201809342YA (en) | Pyrimidine compounds as jak kinase inhibitors | |
| SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
| SG11201808306PA (en) | Treatment of cancer with tg02 | |
| SG11201811442UA (en) | Formulation of a peptide vaccine | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201804123VA (en) | Modulators of kv3 channels to treat pain | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201808762XA (en) | Diagnostic methods for patient specific therapeutic decision making in cancer care | |
| SG11201908114UA (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
| SG11201811482YA (en) | Double targeted constructs to affect tumor kill |